Article

Mmarketwatch.com on 2023-02-28 23:38

FDA approves Reata's rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments3 min read

The approval comes one day after the departure of Billy Dunn, the FDA's head of neuroscience.

Related news

Reata stock soars on FDA approval for ultra-rare disease drug after 15 years Dallas News
Augsburg , Motley , New York , Dallas , Plano
MCelgene's rare disease drug gets FDA approval marketwatch.com
FDA approves CSL Behring rare disease treatment bizjournals.com
FDA grants rare pediatric disease designation to RegenxBio gene therapy bizjournals.com
Teva gets FDA OK for rare disease treatment bizjournals.com
PhaseRx clears hurdle to market with FDA rare disease designation bizjournals.com
Seattle
Cerecor has FDA fast track designation for rare disease drug thedailyrecord.com
Drug for rare form of ALS disease OK’d by FDA ocregister.com
Cambridge , Silver Spring
Shire wins FDA approval for potential blockbuster rare disease drug bizjournals.com
Leadiant gets FDA approval for treatment for rare disease thedailyrecord.com
FDA approves Alnylam's first-ever drug for rare kidney disease bizjournals.com
FDA rejects rare disease drug developed by Cambridge's Akcea bizjournals.com
Cambridge
FDA approves ultra-rare disease drug from Waltham's Sobi bizjournals.com
Sobi , Waltham
FDA gives early OK to Alnylam rare disease drug bizjournals.com
FDA Approves Merck’s New Drug For A Rare Lung Disease Forbes
MSigns point to FDA approval for Biogen’s experimental Alzheimer’s disease treatment, though there are skeptics marketwatch.com
Wall Street
A rare win: North Bay biotech gets FDA approval for drug to treat bone disease bizjournals.com
North Bay
MKaloBios stock jumps on news of positive guidance from FDA on rare disease drug marketwatch.com
São Francisco de Goiás
Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval bizjournals.com
Drug for rare form of Lou Gehrig’s disease OK’d by FDA journalrecord.com
Cambridge